KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Long-Term Investments (2022 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Long-Term Investments for 4 consecutive years, with $37.2 million as the latest value for Q4 2025.

  • Quarterly Long-Term Investments fell 70.86% to $37.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $37.2 million through Dec 2025, down 70.86% year-over-year, with the annual reading at $37.2 million for FY2025, 70.86% down from the prior year.
  • Long-Term Investments for Q4 2025 was $37.2 million at Xenon Pharmaceuticals, down from $93.0 million in the prior quarter.
  • The five-year high for Long-Term Investments was $292.8 million in Q4 2023, with the low at $37.2 million in Q4 2025.
  • Average Long-Term Investments over 4 years is $137.2 million, with a median of $128.9 million recorded in 2022.
  • The sharpest move saw Long-Term Investments soared 127.53% in 2023, then plummeted 70.86% in 2025.
  • Over 4 years, Long-Term Investments stood at $128.7 million in 2022, then skyrocketed by 127.53% to $292.8 million in 2023, then plummeted by 56.46% to $127.5 million in 2024, then tumbled by 70.86% to $37.2 million in 2025.
  • According to Business Quant data, Long-Term Investments over the past three periods came in at $37.2 million, $93.0 million, and $137.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.